Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Verastem Has Deals With Pfizer, Eisai
by Lisa M. Jarvis
July 23, 2012
| A version of this story appeared in
Volume 90, Issue 30
Cambridge, Mass.-based biotech firm Verastem has paid Pfizer an undisclosed sum for rights to PF-04554878, a focal adhesion kinase (FAK) inhibitor that has completed Phase I studies. Verastem has two other FAK inhibitors under development but says the Pfizer deal gives it a “Phase II-ready” drug candidate. In a separate deal, Verastem is collaborating with Eisai to develop small-molecule inhibitors of Wnt, a protein network involved in the development of cancer stem cells. Verastem and Eisai will jointly develop analogs of Verastem’s existing Wnt inhibitor, VS-507.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter